Tag: Vaccine

Categories
Health

Biden Cancels Go to to Vaccine Maker After Instances Report on Its Techniques

Biden Cancels Visit to Vaccine Maker After Times Report on Its Tactics

WASHINGTON – President Biden on Monday canceled a visit to a coronavirus vaccine facility operated by Emergent BioSolutions, and his spokeswoman announced that the administration would conduct an audit of the Strategic National Stockpile, the country’s emergency medical reserve.

Both measures came after a New York Times investigation into how the company gained oversized influence on the repository.

Instead of visiting Emergent’s Baltimore facility on Wednesday, the President will call a meeting at the White House with executives from pharmaceutical giants Merck & Co. and Johnson & Johnson, who should also attend the meeting in Baltimore. Merck and Emergent each work separately with Johnson & Johnson to manufacture the company’s coronavirus vaccine.

“We just felt it was a more suitable place to meet,” White House press secretary Jen Psaki told reporters.

Emergent has signed more than $ 600 million in contracts with the federal government to manufacture coronavirus vaccines and expand its fill-and-finish capacity to complete the vaccine and therapeutic manufacturing process. A senior administration official said only executives from Merck and Johnson & Johnson would attend the White House meeting on Wednesday.

An emergent spokeswoman did not immediately respond to questions about the cancellation on Monday. The spokeswoman, Nina DeLorenzo, had previously defended the company’s dealings with the government in written responses to questions, saying, “If almost no one else invested in preparation to protect the American public from serious threats, Emergent has done so, and the country is better prepared for it today. “

The Times investigation focused on the supply, which became notorious during the coronavirus pandemic for its lack of critical supplies such as N95 masks and other personal protective equipment.

When asked about the Times article during the White House press briefing on Monday, Ms. Psaki said, “The administration will conduct a comprehensive review and review of national inventory levels.”

Decisions about how to spend the repository’s limited budget should be based on careful assessments by government officials on how best to save lives. The Times noted, however, that it was largely driven by the needs and financial interests of a handful of biotech companies specializing in products that target terrorist threats rather than infectious diseases.

Chief among them is Emergent. For most of the past decade, the government has spent nearly half of the annual half-billion dollar inventory budget on Emergent’s anthrax vaccines, The Times noted.

In the competition for funding, pandemic preparation products – including N95 – have repeatedly been lost, according to the Times research, which was based on more than 40,000 pages of documents and interviews with more than 60 people with inside knowledge of inventory levels.

The image of some healthcare workers carrying garbage bags for personal protection has become an enduring symbol of the government’s failed response. Still, the Emergent government paid $ 626 million in 2020 for products containing anthrax vaccines to protect against a terrorist attack.

For much of Emergent’s two-decade history, the lead product was an anthrax vaccine, first approved in 1970 and purchased by the Michigan company in 1998. Over time, the price per dose that the government agreed to pay for Emergent has increased almost sixfold, reflecting inflation.

Ms. DeLorenzo previously defended the company’s pricing as fair. “You can’t protect people from anthrax for less than the cost of a latte,” she wrote in an email.

Emergent’s 2020 sales to the government included a new anthrax vaccine that has not yet been approved as safe and requires special authorization to be stocked. In the months leading up to the coronavirus pandemic, the Trump administration awarded the company long-term contracts worth around $ 3 billion. Last year, the government agreed to pay the company more than $ 600 million to manufacture coronavirus vaccines from other companies at its Baltimore facility. Emergent now manufactures coronavirus vaccines for AstraZeneca as well as Johnson & Johnson.

Emergent, whose board of directors is staffed with former federal officials, has allocated a lobbying budget that is more typical of some large drug companies, according to The Times. Tactics were sometimes resorted to that were considered underhanded even in Washington. For example, competing efforts to develop a better and cheaper anthrax vaccine failed after Emergent outmaneuvered its rivals, documents and interviews show.

Ms. DeLorenzo described the company’s lobbying as “educational” and “appropriate and necessary”.

Categories
Politics

The U.S. Is Sitting on Tens of Tens of millions of Vaccine Doses the World Wants

The U.S. Is Sitting on Tens of Millions of Vaccine Doses the World Needs

“If we have a surplus, we’ll share it with the rest of the world,” Biden told reporters on Wednesday, speaking broadly about US vaccine supplies. “We will first make sure that the Americans are taken care of first.”

Johnson & Johnson, which has US approval for its vaccine but has missed its production targets in both the US and Europe, recently asked the US to loan 10 million doses to the European Union, but the Biden administration this also denied this request to American and European officials.

What you need to know about the vaccine rollout

The European Union has been heavily criticized for “vaccine nationalism” and protectionism, which escalated last week when Italy blocked a small dose delivery to Australia and intensified a tug-of-war over much-needed shots. Still, the European Union has exported 34 million doses of coronavirus vaccines to dozens of countries in the past few weeks despite shortages at home.

As frustrations subside, some European officials blame the United States. European Council President Charles Michel said the United States and Britain had “imposed a total ban on the export of vaccines or vaccine components made on their territory”. Jen Psaki, White House press secretary, was asked Thursday about American delivery of the AstraZeneca vaccine and told reporters that vaccine makers are free to export their US-made products while fulfilling the terms of their contracts with the government .

Since the vaccine was manufactured by AstraZeneca under the Defense Production Act, Mr Biden must authorize the shipment of cans overseas. Such a move could have a huge negative political impact while Americans are still calling for gunfire.

AstraZeneca is also likely to want liability protection for cans shipped overseas, as it would in the US if the vaccine were approved.

In the meantime, regulators in the US have been waiting for new AstraZeneca data, which is expected in the next few weeks from a phase 3 study that enrolled 32,000 participants, mostly in the US. AstraZeneca is unlikely to report results from an early look at its data like other vaccine manufacturers have. Instead, it will wait for more statistically significant results after study participants have been monitored for side effects longer and potentially more people in the vaccine and placebo groups have gotten sick, federal officials said. Experts believe the vaccine is unlikely to be any more potent than the Johnson & Johnson shot, which uses similar technology and only requires one dose.

Categories
Health

J&J’s one-shot Covid vaccine accredited by Europe

J&J's one-shot Covid vaccine approved by Europe

Crystal Jones, 52, head of the Athens City Department of Health, loads syringes of the vaccine on the first day of Johnson and Johnson’s vaccine.

SOPA pictures | LightRocket | Getty Images

The European Medicines Agency on Thursday recommended approval of the one-off coronavirus vaccine developed by Johnson & Johnson, which may add another weapon to the armory used to fight Covid-19.

The vaccine will now be sent to the EU Commission for approval later on Thursday.

The vaccine has the added benefit of only requiring a single dose and can be stored in most standard refrigerators at temperatures of 2 to 8 degrees Celsius (or about 36 to 46 degrees Fahrenheit), making transportation and storage easier and cheaper makes.

Once delivery begins, the shot could add a lot to Europe’s difficult vaccination program and is the fourth to be approved by the EMA. Two-dose vaccines developed by Pfizer-BioNTech, Moderna and AstraZeneca, and Oxford University have also been approved.

While easier to distribute, the vaccine has been found not to be as effective as the Pfizer and Moderna shots in preventing Covid infection. However, the data shows that it offers an adequate level of protection: data from clinical trials from the United States have shown that J & J’s vaccine is 72% effective against moderate to severe Covid (although it has been found to be less effective in studies elsewhere which gives it an overall efficacy of 66% protection) compared to about 95% for the other two vaccines.

The speed at which the EU can introduce the J&J vaccine is not yet clear. The EU has ordered 200 million cans of the shot, with an option for an additional 200 million, Johnson & Johnson said in a statement last October.

However, it was reported on Wednesday that, like other vaccine suppliers in the EU (Pfizer-BioNTech and AstraZeneca), delivery of the J&J vaccine to the block may be slower than expected.

An unnamed EU official told Reuters that Johnson & Johnson had told the EU it was facing supply issues that could complicate plans to deliver 55 million doses of its vaccine to the block in the second quarter of the year. CNBC has contacted J&J for additional comments on the report and has yet to receive a response.

The European Commission, the EU’s executive branch, said on Wednesday that it had not been informed of any delays from J&J.

Another delay in vaccine supply would exacerbate the already lethargic introduction of vaccines in the EU, which has faced issues due to a slower ordering process than the UK and US, slower deliveries, bureaucracy and hesitant vaccines.

In the US, J&J has signed a contract with the US government to supply 100 million cans by the end of June. On Wednesday, the Biden government announced plans to buy an additional 100 million cans. The announcement came as the White House is working to ramp up production of the vaccine after learning earlier this year that the company had fallen behind in production.

Last week, Biden announced that pharmaceutical company Merck would help manufacture J & J’s Covid vaccine. Under the terms of the agreement, Merck will deploy two facilities in the US for J & J’s vaccine. One will make the vaccine and the other will provide “fill-finish” services when the vaccine is put into vials.

– CNBC’s Berkeley Lovelace Jr. contributed to this story.

Correction: This story has been updated to reflect the correct approval process within the EU.

Categories
Business

Denmark suspends use of AstraZeneca Covid vaccine

Denmark suspends use of AstraZeneca Covid vaccine

The Oxford-AstraZeneca Covid vaccine.

Karwai Tang | Getty Images

LONDON – Denmark announced on Thursday that it would temporarily stop using the coronavirus vaccine developed by AstraZeneca and Oxford University.

The Danish health authority said it would temporarily suspend the use of the shot in its vaccination program “following reports of severe cases of blood clots in people vaccinated with AstraZeneca’s COVID-19 vaccine”.

“With this in mind, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. It cannot currently be concluded whether the vaccine is related to the blood clots.” Authority said in a statement.

No information was provided about the number of reports of blood clots or where they came from.

The announcement comes after a similar move in Austria earlier this week, where authorities are investigating one person’s death and another person’s illness after receiving doses of the vaccine.

AstraZeneca’s shares in the London market were down 2.4% on Thursday morning. Oxford University would not comment on the announcement when contacted by CNBC.

An AstraZeneca spokesman said the company was aware of a statement by the Danish health authority that it is investigating possible adverse effects of the vaccine.

“Patient safety is a top priority for AstraZeneca. Regulators have clear and strict standards of efficacy and safety for approving new drugs, including the COVID-19 vaccine AstraZeneca. The vaccine’s safety has been thoroughly investigated in Phase III clinical trials. Review data confirms the vaccine is generally well tolerated, “AstraZeneca said in a statement to CNBC.

Søren Brostrøm, director of the National Health Department in Denmark, insisted that the 14-day suspension was a precautionary measure during the investigation.

“It is important to emphasize that we did not decide against the AstraZeneca vaccine, we are deferring it. There is good evidence that the vaccine is both safe and effective. But both we and the Danish Medicines Agency need to respond Reports of possible serious side effects from both Denmark and other European countries, “he said.

Austria concerns

The Austrian health authorities stopped using batch ABV5300 of the AstraZeneca vaccine after a person was diagnosed with multiple thrombosis (formation of blood clots in blood vessels) and died 10 days after vaccination. Another person was hospitalized with pulmonary embolism after vaccination.

“The latter is now recovering,” said the European Medicines Agency on Wednesday.

However, the EMA added that “there is currently no evidence that vaccination caused these conditions that are not listed as side effects with this vaccine.”

The EMA found that the same batch of ABV5300 was shipped to 17 EU countries and comprised 1 million doses of the vaccine.

“Some EU countries have also suspended this batch as a precautionary measure while a full investigation is in progress. Although a quality defect is considered unlikely at this point, the batch quality will be investigated,” said the EMA.

It added that its safety committee was reviewing the issue and “investigated the cases reported with the batch, as well as all other cases of thromboembolic events and other blood clot-related conditions post-vaccination.”

“The information available so far shows that the number of thromboembolic events in vaccinated people is no higher than in the general population.”

As of March 9, “22 cases of thromboembolic events have been reported among the 3 million people vaccinated with the AstraZeneca COVID-19 vaccine in the European Economic Area,” the EMA said.

Trust in the UK and the EU

In late clinical studies, the AstraZeneca-Oxford shot was found to have an average of 70% effectiveness in protecting against the virus. A recent study by Oxford researchers found that the Covid vaccine was 76% effective at preventing symptomatic infection for three months after a single dose and that the effectiveness rate actually increased with a longer interval between the first and second dose.

The AstraZeneca-Oxford vaccine is widely used in the launch of vaccination in the UK and the European Union.

The UK has so far vaccinated over 22 million people with a first dose of a coronavirus vaccine and is currently only using the AstraZeneca and Pfizer-BioNTech shot.

Categories
Business

Texas opens Covid vaccine eligibility to individuals 50 and older because it lifts masks mandate

UK coronavirus variant 'on course to sweep the world,' geneticist says

Ron Votral will receive a vaccine against coronavirus disease (COVID-19) at a drive-through vaccination site in Robstown, Texas on February 9, 2021.

Go Nakamura | Reuters

Texas residents 50 and older can get Covid-19 vaccines starting March 15. This is the most populous US state, which extends the eligibility to the previous age group, the state Department of Health said on Wednesday.

So far, Texas has given frontline health workers, people with underlying health conditions, and those 65 and over the opportunity to get a shot. The state announced last week that it would immediately add school and child carers to its list of vaccination entitlements.

By extending the eligibility to people over 50, the state wants to protect those most at risk of serious illnesses from the virus, the ministry said in a statement. The move will put 5 million more Texans on the state’s priority list, even though more than 1 million of them have already been vaccinated.

“The extension to ages 50-64 will continue the state’s priorities of protecting those at greatest risk of serious consequences and preserving the state’s health system,” said Imelda Garcia, deputy commissioner for the ministry of state Health services for laboratory and infectious diseases made a statement.

More than half of the state’s seniors have received at least one dose of vaccine, and nearly a third are fully vaccinated, according to DSHS.

Wednesday also marked the end of the Lone Star State’s mask mandate, and companies are now 100% allowed to reopen, Governor Greg Abbott announced last week, pointing to the increase in vaccine eligibility, the decrease in new cases and the state’s adequate hospital capacity Argumentation.

Alaska became the first state on Tuesday to allow residents 16 and older to be vaccinated.

Categories
Health

Biden Covid staff holds briefing as U.S. plans to purchase extra J&J vaccine doses

Biden Covid team holds briefing as U.S. plans to buy more J&J vaccine doses

[The stream is slated to start at 11 a.m. ET. Please refresh the page if you do not see a player above at that time.]

President Joe Biden’s Covid-19 Response Team holds a press conference Wednesday on the coronavirus pandemic that infected more than 29 million Americans and killed at least 527,720 people in just over a year.

Two government sources told NBC News that the U.S. government plans to buy 100 million additional doses of the Covid-19 vaccine from Johnson & Johnson. Biden will announce the plans on Wednesday during a White House meeting with executives from J&J and Merck.

J&J currently has a contract with the US government to provide 100 million cans by the end of June. The federal government shipped nearly 3.9 million doses of the single vaccine last week and plans to distribute an additional 16 million by the end of this month.

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
Health

J&J Covid vaccine distribution in poor, Black communities raises race questions

J&J Covid vaccine distribution in poor, Black communities raises race questions

Johnson & Johnson Covid-19-Impfstoff in einem Impfzentrum, das am 5. März 2021 im Hilton Chicago O’Hare Airport Hotel in Chicago, Illinois, eingerichtet wurde.

Kamil Krzaczynski | AFP | Getty Images

Logan Patmon aus Detroit weiß, dass der Covid-19-Impfstoff von Johnson & Johnson einfacher zu verteilen ist als die Schüsse von Moderna und Pfizer.

Der 28-jährige Black-Anwalt sagte, er sehe es als minderwertig an, da Daten aus klinischen Studien gezeigt haben, dass J & J in den USA zu 72% gegen Covid schützt, verglichen mit etwa 95% bei den beiden anderen Impfstoffen.

“Warum für 70 gehen, wenn Sie 95 bekommen können?” er sagte.

Für Beamte ist der Schuss von J & J ein Segen, da er monatelang bei Kühlschranktemperatur gelagert werden kann und nur eine Dosis benötigt – im Gegensatz zu Pfizer und Moderna, für die Gefrierschränke und zwei Runden Stöße im Abstand von etwa einem Monat erforderlich sind. Das macht J & Js Schuss zu einem wichtigen Instrument, um Menschen, die möglicherweise nicht zu einem zweiten Termin zurückkehren können, lebensrettende Impfstoffe zukommen zu lassen. Es ist besonders wertvoll, um die Aufnahmen an schwer erreichbare Orte zu bringen, an denen möglicherweise keine zuverlässige Kühlung vorhanden ist, z. B. in Stammesgebieten, in ärmeren Gegenden sowie in ländlichen und Grenzgemeinden.

“Nur weil es am einfachsten ist, heißt das nicht, dass es das Richtige ist”, sagte Patmon gegenüber CNBC. “Sie möchten nicht, dass es eine Situation gibt, in der getrennte, wohlhabendere Gebiete den besseren Impfstoff erhalten und den armen, mehr Minderheitengebieten gesagt wird: ‘Sei einfach glücklich.'”

Beamte stoßen bei der Verteilung der Aufnahmen von J & J auf ein unvorhergesehenes Problem. Obwohl unbeabsichtigt, stellen einige Leute aufgrund ihrer niedrigeren Wirksamkeitsrate die Frage, ob dies nur ein weiteres Beispiel für eine subtil rassistische Behandlung von Minderheiten in Amerika ist. Während der Impfstoff von J & J hochwirksam ist, insbesondere gegen schwere Krankheiten und Todesfälle, sehen Patmon und andere Amerikaner ihn immer noch als minderwertig an. Durch den Versand an ärmere Postleitzahlen in Großstädten und ländlichen Gemeinden riskieren Beamte laut Gesundheitsexperten Vorwürfe der Diskriminierung.

Dies könnte das Vertrauen in die Einführung von Impfstoffen weiter untergraben, insbesondere in Farbgemeinschaften, sagen Experten, da mehr Daten aus Staaten zeigen, dass Schwarze und Hispanics weiterhin einen überproportionalen Anteil an Covid-19-Todesfällen ausmachen, die Impfstoffe jedoch mit deutlich geringeren Raten erhalten als Weiße Menschen.

In New York zum Beispiel machen Schwarze etwa 16% der Bevölkerung des Bundesstaates aus und machen 23% der Todesfälle durch Covid-19 aus, haben aber laut einem Bericht des gemeinnützigen Kaisers vom 3. März bisher nur 8% der Schüsse erhalten Family Foundation, die staatlich gemeldete Daten analysierte. Hispanics machen 19% der Bevölkerung und 23% der Todesfälle in Covid aus, haben aber nur 9% der Schüsse erhalten.

Weiße Menschen machen 63% der Bevölkerung und 40% der Todesfälle aus, aber laut KFF-Analyse haben sie 81% der Impfungen erhalten.

Die Verwendung des Impfstoffs von J & J hauptsächlich in schwer erreichbaren Gebieten kann zu einem “Maß an Misstrauen” und “erhöhtem Zögern” führen, sagte Dr. Sonja Hutchins, eine ehemalige CDC-Beamtin, am 1. März gegenüber dem Beratenden Ausschuss für Immunisierungspraktiken der Agentur sehr vorsichtig zu sein und zu verstehen, was einige der unbeabsichtigten Folgen der Ausrichtung auf Farbgemeinschaften sein könnten, von denen einige glauben, dass sie schwer zu lesen sind, wenn sie erreichbar sind “, sagte Hutchins, der jetzt Professor an der Morehouse School of Medicine ist.

Impfstoffe vergleichen

Der Impfstoff von J & J wurde am 27. Februar für die Verwendung in den USA zugelassen. Der J & J-Schuss zeigte in den USA etwa einen Monat nach der Inokulation eine Wirksamkeit von 72%, 66% in Lateinamerika und 64% in Südafrika, wo das ansteckendere und virulentere B. Die Variante .1.351 breitet sich schnell aus. Insbesondere verhinderte es 100% der virusbedingten Krankenhausaufenthalte und Todesfälle. Die klinischen Phase-3-Studien von Pfizer und Moderna, die im November abgeschlossen wurden, zeigten, dass beide Impfstoffe eine Wirksamkeitsrate von etwa 95% aufwiesen.

Die Berechnung der Wirksamkeit eines Impfstoffs ist schwierig und kann variieren, je nachdem, wo die Studie durchgeführt wird, welche Arten von Varianten in der Region vorherrschen und wie weit die Gemeinschaft verbreitet ist.

Die dritte Phase der Studie von J & J begann ungefähr zwei Monate hinter der von Pfizer und Moderna und wurde weltweit und in Ländern durchgeführt, in denen bereits infektiösere Varianten, die sich den Impfstoffen entziehen können, bereits eingesetzt hatten.

Dr. Anthony Fauci, Chefarzt des Weißen Hauses, sagte, es sei unmöglich, die drei zu vergleichen, da sie nicht in direkten klinischen Studien bewertet wurden.

“Wir sagen also nicht, dass einer besser oder schlechter ist als der andere, wir sagen, dass alle drei wirklich ziemlich gut sind”, sagte er am Samstag gegenüber MSNBC. “In Bezug auf die Verbreitung in verschiedenen Gruppen hat der Präsident sehr, sehr deutlich gemacht, dass wir Gerechtigkeit haben werden, was bedeutet, dass wir diese gleichmäßig auf die verschiedenen Komponenten verteilen werden, genauso wie wir es mit den anderen beiden getan haben . “

Er sagte, jemand könnte den Impfstoff von J & J bevorzugen, weil nur ein Schuss erforderlich ist, “aber es wird keine absichtliche Versendung an eine demografische Gruppe gegenüber einer anderen geben”, sagte er.

Die Bundesregierung hat letzte Woche fast 4 Millionen Dosen des Impfstoffs von J & J an Bundesstaaten, Apotheken und kommunale Gesundheitszentren verteilt und plant, bis Ende dieses Monats weitere 16 Millionen zu versenden. Das Unternehmen hat bis Ende Juni einen Vertrag mit der US-Regierung über 100 Millionen Dosen abgeschlossen.

Ein wichtiges Verkaufsargument für den Impfstoff von J & J ist, dass er mindestens 3 Monate bei 36 bis 46 Grad Fahrenheit gelagert werden kann und eine Einzeldosis ist. Im Vergleich dazu handelt es sich bei den Impfstoffen von Pfizer und Moderna um zwei Dosierungen. Pfizers Schuss muss in ultrakalten Gefrierschränken gelagert werden, die zwischen minus 112 und minus 76 Grad Fahrenheit liegen, obwohl die FDA dem Unternehmen kürzlich gestattet hat, ihn zwei Wochen lang bei Temperaturen zu lagern, die üblicherweise in pharmazeutischen Gefriergeräten zu finden sind. Moderna muss mit 13 unter null bis 5 Grad Fahrenheit verschickt werden.

Zuordnung zu Staaten

Jeff Zients, Covid-Zar von Präsident Joe Biden, sagte, dass der Impfstoff von J & J Staaten auf der Grundlage ihrer gesamten erwachsenen Bevölkerung zugeteilt wird – genau wie Pfizer und Moderna. Sobald der Impfstoff eingetroffen ist, können die Staaten die Dosen nach eigenem Ermessen verteilen, obwohl die CDC empfiehlt, die am stärksten gefährdeten Personen zu priorisieren.

In New York City sagte Bürgermeister Bill de Blasio, der J & J-Impfstoff sei für Senioren im Heimatland und andere bestimmt, die nicht einfach zu Vertriebszentren gelangen können. Er räumte ein, dass der Impfstoff aufgrund seiner geringeren Wirksamkeitsrate eine “Kommunikationsherausforderung” für staatliche und lokale Gesundheitsbehörden darstellen könnte.

“Es gibt viele Fehlinformationen, die wir überwinden müssen”, sagte er am 1. März gegenüber Reportern. “Sobald Sie geimpft sind, sind Sie geschützt. Es macht so viel Sinn, sie zu verwenden. Und das macht mir wirklich Sorgen.” Die Leute werden das falsche Verständnis davon bekommen und dann zögern, sich genau dann impfen zu lassen, wenn wir sie am dringendsten brauchen, um geimpft zu werden. “

In Louisville, Kentucky, sagten Gesundheitsbeamte, sie würden den Impfstoff für vorübergehende Menschen einsetzen, die einem hohen Risiko ausgesetzt sind und nicht einfach für einen zweiten Schuss zurückkehren können, wie die Obdachlosen. In Harris County, Texas, wo sich Houston befindet, wird der J & J-Impfstoff an mobilen Impfstellen verabreicht, die jede Woche den Standort wechseln, wenn Anbieter versuchen, unterversorgte Gruppen zu erreichen, die am anfälligsten für Covid sind.

Der Bürgermeister von Detroit, Mike Duggan, lehnte letzte Woche eine erste Zuteilung des Impfstoffs von J & J ab und sagte: “Johnson & Johnson ist ein sehr guter Impfstoff. Moderna und Pfizer sind die besten. Und ich werde alles tun, um sicherzustellen, dass die Bewohner der Stadt von Detroit bekommen das Beste. “

Später ging er diese Kommentare zurück und teilte CNBC in einer Erklärung mit, dass die Stadt bereits über genügend Kapazitäten mit Moderna und Pfizer verfügt, um Tausende von Einwohnern zu impfen. Er sagte, die Stadt werde eine neue Impfstelle für J & J-Aufnahmen eröffnen, wenn die Nachfrage der berechtigten Bewohner das Angebot an Moderna- und Pfizer-Dosen übersteigt.

“Sehr vorsichtig”

Kasisomayajula Viswanath, Professor für Gesundheitskommunikation an der Harvard TH Chan School of Public Health, sagte gegenüber CNBC, er sei besorgt darüber, wie Staaten den Impfstoff verteilen würden, auch wenn ihr Plan sinnvoll sei.

Viswanath, dessen Forschung sich auf die Beseitigung von Ungleichheiten im Gesundheitswesen konzentriert, sagte, dass staatliche und lokale Gesundheitsbehörden mitteilen müssen, warum der Impfstoff von J & J auf eine bestimmte Weise verteilt wird, oder dass sie Vorwürfe von Rassismus und Misstrauen riskieren.

“Wir müssen äußerst vorsichtig sein”, sagte er und fügte hinzu, dass die Impfstoffe von Moderna und Pfizer J & J überlegen seien.

Viswanath empfahl den Staaten, die Hilfe lokaler Organisationen, denen Gemeinschaften vertrauen, wie Kirchen oder Aktivistengruppen, für ihre Kommunikationsbemühungen zu gewinnen.

“Wenn Sie anfangen, diesen Impfstoff an bestimmte Gruppen und bestimmte Stadtteile zu verteilen, ohne zu erklären, warum dies so gemacht wird, besteht wahrscheinlich die Wahrnehmung, dass meine Gruppe, meine Nachbarschaft, meine Stadt diesen Impfstoff mit geringer Wirksamkeit im Vergleich zu erhält diese Gruppe, diese Nachbarschaft oder diese Stadt “, sagte er.

Insbesondere in schwarzen Gemeinden gibt es bereits Bedenken aufgrund der anhaltenden Diskriminierung, die sie “Tag für Tag” vom Gesundheitssystem erfahren, sagte er.

“Die tägliche Diskriminierung, die tägliche Respektlosigkeit, das ist es, was Misstrauen erzeugt”, sagte er.

Umdenken

Dr. Stephen Schrantz, der Teil des Teams war, das eine J & J-Impfstoffstudie an der Medizin der Universität von Chicago leitete, sagte, Kommunikation sei der Schlüssel. Er fügte hinzu, dass Anbieter nicht möchten, dass ihre Patienten glauben, sie würden “einen wirksameren Impfstoff erhalten als eine andere Person”.

Die Wahrnehmung der Menschen kann sich ändern, fügte er hinzu, zumal mehr Daten über die Impfstoffe herauskommen und die Menschen von den Menschen ihre eigenen inneren Kreise hören.

Veronica Takougang, eine schwarze Medizinstudentin im ersten Jahr in Cincinnati, sagte, sie habe von Gleichaltrigen und anderen viele Bedenken über den J & J-Impfstoff gehört und darüber, ob er vorwiegend in Farbgemeinschaften eingesetzt wird.

Sie sagte, dass sie den Menschen sagt, dass der Impfstoff viele Vorteile hat, einschließlich der Tatsache, dass er schwere Krankheiten verhindert und eine Einzeldosis darstellt, so dass etwa einen Monat später kein zweiter Termin vereinbart werden muss.

“Die Leute achten sehr auf die Zahlen”, sagte sie. Sie fügte hinzu, dass ihre Bedenken hinsichtlich des Impfstoffs von J & J “gültig” seien und dass Menschen nicht davon ausgeschlossen werden sollten, die anderen Impfstoffe zu erhalten, nur weil sie möglicherweise nicht in der Lage sind, eine zusätzliche Stunde frei zu nehmen.

Geimpft werden

Das Weiße Haus fordert die Öffentlichkeit auf, den ersten Impfstoff zu nehmen, den Sie bekommen können.

“Wir haben drei hochwirksame Impfstoffe mit einem sehr guten Sicherheitsprofil”, sagte Fauci am Freitag gegenüber Reportern. “Jeder von ihnen ist sehr wirksam bei der Vorbeugung klinisch offensichtlicher Krankheiten. Wichtig ist jedoch, dass alle drei einen sehr wichtigen Effekt haben, da sie außerordentlich wirksam gegen schwere Krankheiten sind und Krankenhausaufenthalte und Todesfälle verhindern.”

“Das Wichtigste ist, sich impfen zu lassen und nicht herauszufinden, ob einer besser ist als der andere”, fügte er hinzu.

Alex Gorsky, CEO von J & J bei CNBC, sprach am 1. März ebenfalls über die niedrigere Wirksamkeitsrate und sagte, der Impfstoff werde ein wichtiges Instrument im Kampf gegen das Virus sein, da er Krankenhausaufenthalte und Todesfälle verhindert.

“Es gibt viele verschiedene Möglichkeiten, Vergleiche anzustellen”, sagte Gorsky in einem Interview mit CNBCs “Squawk Box”. “Aber wenn man sich wirklich ansieht, was hier das Ziel ist, Menschen aus dem Krankenhaus herauszuhalten und Menschen vor dem Sterben zu bewahren, glauben wir, dass dies ein unglaublich wichtiges Instrument ist, das hinzugefügt werden muss – zu Gesundheitssystemen, geschweige denn zu Patienten auf der ganzen Welt.”

Categories
Business

U.S. Progress Might Double in 2021, Bolstered by Vaccine and Stimulus

U.S. Growth Could Double in 2021, Bolstered by Vaccine and Stimulus

The American economy is set to accelerate nearly twice as fast this year as expected as President Biden’s imminent $ 1.9 trillion stimulus package, coupled with a swift introduction of vaccines, sparks a strong rebound from the pandemic the Organization for Economic Cooperation and Development announced on Tuesday.

However, countries stumbling at the pace of their vaccination campaigns, especially those in Europe, are at risk of falling behind in global recovery as governments are not forced to push back the spread of the virus in order to return to normal lives, the said Organization.

In its half-year outlook, the organization said the United States would expand 6.5 percent this year, a sharp increase from the 3.2 percent forecast in December. The upswing in the world’s largest economy will generate enough momentum to increase global production by 5.6 percent from 3.4 percent in 2020.

China, which contained the virus earlier than other countries, remains a big global winner with forecast growth of 7.8 percent.

Although a global recovery is in sight, government spending to boost their economies will have limited impact unless authorities accelerate national vaccine rollouts and ease virus containment measures, the report added. When vaccination programs aren’t fast enough to reduce infection rates, or when new varieties become more prevalent and vaccine changes are required, consumer spending and business confidence will be hurt.

“Vaccine-free stimuli are not as effective because consumers don’t do normal things,” said Laurence Boone, chief economist at the OECD, in an online press conference. “It’s the combination of health and financial policy that matters.”

This is particularly true in Europe, and particularly Germany and France, where a mix of poor public health management and slow vaccination programs is weighing on the recovery despite billions in government support. Such spending “will not be fully effective until the economy reopens,” said Ms. Boone.

The euro area economy is expected to grow 3.9 percent this year, slightly more than forecast in December, but more slowly than the US. In the UK, which accelerated a national vaccination rollout late last year, economic growth is expected to be 5.1 percent, compared with a forecast of 4.2 percent.

India’s economy is expected to grow 12.6 percent after falling 7.4 percent in 2020, the organization added.

Categories
Health

Biden Covid staff holds briefing after White Home strikes up vaccine provide timeline

Biden Covid team holds briefing after White House moves up vaccine supply timeline

[The stream is slated to start at 11 a.m. ET. Please refresh the page if you do not see a player above at that time.]

President Joe Biden’s Covid-19 Response Team holds a press conference Wednesday on the coronavirus pandemic that infected more than 28 million Americans and killed at least 516,616 people in just over a year.

On Tuesday, Biden announced that the U.S. will have sufficient supplies of Covid-19 vaccines to vaccinate every adult in the nation by the end of May – two months earlier than expected. He also called on states to prioritize vaccinating teachers and school staff against Covid-19, with the aim of giving at least one shot to every educator and staff member across the country by the end of March.

“Let me be clear, we can reopen schools if the right steps are taken before staff are vaccinated,” Biden said at the White House on Tuesday. “But time and again we have heard from educators and parents who are concerned about it.”

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

–CNBC’s Will Feuer contributed to this report.

Categories
Health

EU covid vaccine below highlight as Italy blocks cargo to Australia

EU covid vaccine under spotlight as Italy blocks shipment to Australia

Prepared syringes at the Brussels Expo Covid-19 vaccination center in Brussels, Belgium, on Friday March 5, 2021.

Bloomberg | Bloomberg | Getty Images

LONDON – Europe’s launch of coronavirus vaccines has once again been in the spotlight after the Italian government blocked a shipment of Oxford-AstraZeneca vaccines to Australia.

The EU has made an effort to spread Covid-19 shots across the 27-person region and is lagging behind other advanced economies in terms of the number of vaccinations per citizen. There have been complaints that regulators are too slow to approve vaccines, manufacturing and delivery issues, and bureaucratic issues that are hampering the process.

However, new questions were raised on Thursday when Italy became the first EU country to apply the bloc’s new rules that allow exports to be halted if necessary. The move stopped around 250,000 doses of the vaccine from its Anagni, Italy facility that was being shipped to Australia.

The introduction of vaccines in Europe “will be an uphill battle,” Daniel Gros, director of the think tank at the Center for European Policy Studies in Brussels, Belgium, told CNBC on Friday.

How the EU got here

At the end of January, the EU announced new rules that would allow European member states that manufacture coronavirus shots to ban their exports in the event that the pharmaceutical company concerned fails to comply with existing contracts with the bloc.

The EU and AstraZeneca were at odds with the drugmaker unable to fire as many shots as the bloc expected for the first quarter. There were also doubts about how many shots the company will deliver in the second quarter.

The EU is being toasted for what the US is doing in a more radical form.

Daniel Gros

Director of CEPS

Pascal Soriot, CEO of AstraZeneca, said late last month that the vaccine shortage was due to yield issues and that his company was working around the clock to increase production.

French Health Minister Olivier Veran said on Friday morning that France could repeat Italy’s step. Federal Health Minister Jens Spahn said there had been no reason to stop shipping vaccines made in Germany to other countries, according to Reuters.

Ursula von der Leyen, President of the European Commission, said last month that around 95% of EU vaccines exported since late January were made by Pfizer-BioNTech and Moderna, as both companies respected their agreement with the EU.

At the time, she also said the US and UK had systems in place to block exports of these vaccines.

Europe is being “roasted” for what others are doing too

“The EU is being roasted for something that the US is doing in a more radical form,” said Gros from the CEPS.

“The amount was tiny. But as always, people jump on symbols. The US doesn’t have the problem of having to stop vaccines at the border because no one would think of exporting anything from the US,” he added.

In an executive order in early December, then-President Donald Trump ordered that the US should only export vaccines made in the country once it was determined that there were sufficient doses to vaccinate the American population.

“Now that it is determined that there is adequate supply of COVID-19 vaccine doses for all Americans who choose to vaccinate, allies, partners and others need to facilitate international access to COVID-19 vaccines for the US government and in accordance with applicable law, “says the regulation.

Delivery to Australia has been blocked as the country is not on the EU’s list of nations at risk. The EU regulation exempts distribution to poorer nations from being blocked by the member states.

Australian Prime Minister Scott Morrison said at a news conference Friday that the country’s vaccination program would “continue unabated”, adding that the broadcast in question was not what they had anticipated for the rollout.

Australia has reportedly asked the European Commission to review Italy’s decision to block the broadcast. However, Morrison admitted that he understood why there would be high levels of concern in Italy and across Europe.

“We should not forget that the EU is providing vaccines for the south of the world and at the same time preventing this delivery to Australia,” Alberto Alemanno, professor of European law at HEC Paris, told CNBC on Friday.

He added that “the EU export control regulation embodies the EU’s legitimate attempt to gain some sovereign autonomy”.